A239061B-989B-4F2F-BAAC-13BADFDBAC11
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.09855453350854139
- age_years
- 34
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.596
- MYC_TARGETS_V2+0.552
- INTERFERON_GAMMA_RESPONSE+0.499
- ALLOGRAFT_REJECTION+0.459
- MYC_TARGETS_V1+0.457
- E2F_TARGETS+0.445
- DNA_REPAIR+0.442
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.426
- NOTCH_SIGNALING+0.376
- G2M_CHECKPOINT+0.342
Top 10 suppressed
- SPERMATOGENESIS-0.329
- KRAS_SIGNALING_DN-0.310
- UV_RESPONSE_DN-0.306
- ESTROGEN_RESPONSE_EARLY-0.207
- PANCREAS_BETA_CELLS-0.130
- ANDROGEN_RESPONSE-0.120
- MYOGENESIS-0.091
- APICAL_SURFACE-0.077
- PROTEIN_SECRETION-0.075
- HEDGEHOG_SIGNALING-0.053
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 33E877FA-0480-407C-B1FD-16A385B797B4 | — | — | 0.937 |
| 2 | E00A399D-E6C3-439D-8E70-A7AD5DF5F5E2 | — | — | 0.929 |
| 3 | 4EA4A8AE-581A-4170-8062-99645CB41337 | — | — | 0.920 |
| 4 | 91E04630-B2A7-448E-8C80-580818C9D7E6 | — | — | 0.915 |
| 5 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.914 |
| 6 | A781FFD8-8A8D-4818-BD90-674295BE64D6 | — | — | 0.913 |
| 7 | D1729A17-148B-4C58-BEB5-7C4349A0E920 | — | — | 0.912 |
| 8 | FD3CFD0E-E8D9-4A57-A9F0-4FB519B7E459 | — | — | 0.909 |
| 9 | A541B123-A51C-4EF0-839E-8A9513311C98 | — | — | 0.908 |
| 10 | 821FCEC2-41D4-48D9-8B75-D87405D075F7 | — | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.596 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.552 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.499 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.459 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.457 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.445 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.442 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.426 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.376 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.342 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.341 | Inavolisib | — uncovered |
| APOPTOSIS | 0.336 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.332 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.303 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.294 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.281 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.267 | Remibrutinib | — uncovered |
| COAGULATION | 0.267 | Binimetinib | — uncovered |
| COMPLEMENT | 0.266 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.259 | Inavolisib | — uncovered |